168 related articles for article (PubMed ID: 21796123)
1. Angiotensin II receptor blocker and long-acting calcium channel blocker combination therapy decreases urinary albumin excretion while maintaining glomerular filtration rate.
Nakagawa N; Fujino T; Kabara M; Matsuki M; Chinda J; Kikuchi K; Hasebe N;
Hypertens Res; 2011 Oct; 34(10):1121-6. PubMed ID: 21796123
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
Maeda A; Tamura K; Kanaoka T; Ohsawa M; Haku S; Azushima K; Dejima T; Wakui H; Yanagi M; Okano Y; Fujikawa T; Toya Y; Mizushima S; Tochikubo O; Umemura S
Clin Exp Hypertens; 2012; 34(4):249-57. PubMed ID: 22571446
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of hypertension treatment: controlled release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension--the Nifedipine and Candesartan Combination (NICE-Combi) Study.
Fujikawa K; Hasebe N; Kikuchi K;
Hypertens Res; 2005 Jul; 28(7):585-91. PubMed ID: 16335887
[TBL] [Abstract][Full Text] [Related]
4. Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients.
Ishimitsu T; Kobayashi T; Honda T; Takahashi M; Minami J; Ohta S; Inada H; Yoshii M; Ono H; Matsuoka H
Hypertens Res; 2005 Apr; 28(4):351-9. PubMed ID: 16138566
[TBL] [Abstract][Full Text] [Related]
5. Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria.
Okura T; Kojima M; Machida H; Sugiyama M; Kato T; Komada T; Miyazaki T; Ninomiya T; Ichikawa T; Nakatani K; Watanabe Y; Dohi Y; Ito M; Kimura G
J Hum Hypertens; 2012 Apr; 26(4):214-9. PubMed ID: 21412266
[TBL] [Abstract][Full Text] [Related]
6. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study.
Hasebe N; Kikuchi K;
J Hypertens; 2005 Feb; 23(2):445-53. PubMed ID: 15662234
[TBL] [Abstract][Full Text] [Related]
7. An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency.
Nakamura T; Kanno Y; Takenaka T; Suzuki H;
Hypertens Res; 2005 May; 28(5):415-23. PubMed ID: 16156505
[TBL] [Abstract][Full Text] [Related]
8. Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria.
Fogari R; Corradi L; Zoppi A; Lazzari P; Mugellini A; Preti P; Rinaldi A
Am J Hypertens; 2007 Oct; 20(10):1092-6. PubMed ID: 17903693
[TBL] [Abstract][Full Text] [Related]
9. Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-combi) study.
Saito I; Saruta T;
Hypertens Res; 2006 Oct; 29(10):789-96. PubMed ID: 17283866
[TBL] [Abstract][Full Text] [Related]
10. Manidipine treatment in patients with albuminuria not sufficiently reduced with renin-angiotensin system blockers.
Galceran J; Plana J; Felip A; Pou G; Vila J; Sobrino J
Expert Rev Cardiovasc Ther; 2010 Jun; 8(6):751-7. PubMed ID: 20528630
[TBL] [Abstract][Full Text] [Related]
11. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
[TBL] [Abstract][Full Text] [Related]
13. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
Sato A; Tabata M; Hayashi K; Saruta T
Clin Exp Nephrol; 2003 Sep; 7(3):215-20. PubMed ID: 14586718
[TBL] [Abstract][Full Text] [Related]
14. Determinants of urinary albumin excretion reduction in essential hypertension: A long-term follow-up study.
Pascual JM; Rodilla E; Miralles A; Gonzalez C; Redon J
J Hypertens; 2006 Nov; 24(11):2277-84. PubMed ID: 17053551
[TBL] [Abstract][Full Text] [Related]
15. Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study.
Katayama S; Yagi S; Yamamoto H; Yamaguchi M; Izumida T; Noguchi Y; Inaba M; Inukai K
Hypertens Res; 2007 Jun; 30(6):529-33. PubMed ID: 17664856
[TBL] [Abstract][Full Text] [Related]
16. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
Fujisawa T; Ikegami H; Ono M; Nishino M; Noso S; Kawabata Y; Ogihara T
Am J Hypertens; 2005 Jan; 18(1):13-7. PubMed ID: 15691611
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial comparing the effects of a low-dose combination of nifedipine GITS and valsartan versus high-dose monotherapy on central hemodynamics in patients with inadequately controlled hypertension: FOCUS study.
Park JB; Ha JW; Jung HO; Rhee MY;
Blood Press Monit; 2014 Oct; 19(5):294-301. PubMed ID: 24915052
[TBL] [Abstract][Full Text] [Related]
18. Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria.
Morgan T; Anderson A; Bertram D; MacInnis RJ
J Renin Angiotensin Aldosterone Syst; 2004 Jun; 5(2):64-71. PubMed ID: 15295717
[TBL] [Abstract][Full Text] [Related]
19. Low-grade albuminuria reduction with angiotensin II type 1 receptor blocker in renal transplant recipients.
Uchida J; Machida Y; Iwai T; Iguchi T; Kamada Y; Naganuma T; Kumada N; Kim T; Kawashima H; Nakatani T
J Nephrol; 2011; 24(4):515-21. PubMed ID: 21240871
[TBL] [Abstract][Full Text] [Related]
20. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
Nutahara K; Higashihara E; Horie S; Kamura K; Tsuchiya K; Mochizuki T; Hosoya T; Nakayama T; Yamamoto N; Higaki Y; Shimizu T
Nephron Clin Pract; 2005; 99(1):c18-23. PubMed ID: 15637459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
